https://rheumatologydigest.org/tags/fcrn/Recent content in Fcrn on Rheumatology DigestHugoen-usTue, 21 Jul 2026 05:00:00 +0530https://rheumatologydigest.org/posts/rho-efgartigimod-sjogrens/Tue, 21 Jul 2026 05:00:00 +0530https://rheumatologydigest.org/posts/rho-efgartigimod-sjogrens/RHO is a phase 2 proof-of-concept RCT of the FcRn antagonist efgartigimod in Sjögren’s disease, testing whether removing pathogenic IgG autoantibodies improves disease. It met its exploratory objective (CRESS response 45.5% vs 11.1% at week 24) with deep, selective IgG reduction — but systemic activity improved while patient-reported symptoms did not, and the tiny sample means this justifies phase 3, not practice change.